These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38719549)

  • 1. Effects of prednisolone tapering on effectiveness of infliximab in patients with ulcerative colitis: data from a retrospective cohort.
    Ovesen PD; Attauabi M; Ilvemark JFKF; Wewer MD; Warren DJ; Burisch J; Klaasen RA; Bolstad N; Steenholdt C; Seidelin JB
    BMJ Open Gastroenterol; 2024 May; 11(1):. PubMed ID: 38719549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensified Infliximab Induction is Associated with Improved Response and Decreased Colectomy in Steroid-Refractory Paediatric Ulcerative Colitis.
    Church PC; Ho S; Sharma A; Tomalty D; Frost K; Muise A; Walters TD; Griffiths AM
    J Crohns Colitis; 2019 Aug; 13(8):982-989. PubMed ID: 30715240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial.
    Balram B; Joshi H; Wong K; Kroeker KI; Dieleman LA; Halloran BP; Baumgart DC; Peerani F
    Dig Dis Sci; 2021 Nov; 66(11):3985-3992. PubMed ID: 33184796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis.
    Kevans D; Murthy S; Mould DR; Silverberg MS
    J Crohns Colitis; 2018 May; 12(6):662-669. PubMed ID: 29659758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
    Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study.
    Hupé M; Streichenberger A; Wils P; Arab N; Serrero M; Amiot A; Bozon A; Vuitton L; Fumery M; Altwegg R; Nachury M; Hébuterne X; Yzet C; Coban D; Dodel M; Bazoge M; Pereira B; Buisson A
    Dig Liver Dis; 2024 Aug; 56(8):1312-1318. PubMed ID: 38281870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysis.
    Nalagatla N; Falloon K; Tran G; Borren NZ; Avalos D; Luther J; Colizzo F; Garber J; Khalili H; Melia J; Bohm M; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):502-509.e1. PubMed ID: 29944926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
    Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A
    World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study.
    Fiorino G; Cortes PN; Ellul P; Felice C; Karatzas P; Silva M; Lakatos PL; Bossa F; Ungar B; Sebastian S; Furfaro F; Karmiris K; Katsanos KH; Muscat M; Christodoulou DK; Maconi G; Kopylov U; Magro F; Mantzaris GJ; Armuzzi A; Boscà-Watts MM; Ben-Horin S; Bonovas S; Danese S
    Clin Gastroenterol Hepatol; 2016 Oct; 14(10):1426-1432.e1. PubMed ID: 27317850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study.
    Barberio B; Zingone F; D'Incà R; Rovigo L; Bertani L; Bodini G; Ghisa M; Gubbiotti A; Massimi D; Lorenzon G; Savarino EV
    Clin Transl Gastroenterol; 2020 May; 11(5):e00177. PubMed ID: 32677808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
    Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S
    J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J; Detlie TE; Vatn S; Ricanek P
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis.
    Murthy SK; Greenberg GR; Croitoru K; Nguyen GC; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2015 Sep; 21(9):2090-6. PubMed ID: 26099066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus.
    Tsukamoto H; Tanida S; Mizoshita T; Ozeki K; Ebi M; Shimura T; Mori Y; Kataoka H; Kamiya T; Joh T
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):714-8. PubMed ID: 23411870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    J Crohns Colitis; 2018 Nov; 12(11):1316-1325. PubMed ID: 30239644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab induction regimens in steroid-refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis.
    Sebastian S; Myers S; Argyriou K; Martin G; Los L; Fiske J; Ranjan R; Cooper B; Goodoory V; Ching HL; Jayasooriya N; Brooks J; Dhar A; Shenoy AH; Limdi JK; Butterworth J; Allen PB; Samuel S; Moran GW; Shenderey R; Parkes G; Lobo A; Kennedy NA; Subramanian S; Raine T
    Aliment Pharmacol Ther; 2019 Sep; 50(6):675-683. PubMed ID: 31456297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis.
    Ungar B; Mazor Y; Weisshof R; Yanai H; Ron Y; Goren I; Waizbard A; Yavzori M; Fudim E; Picard O; Loebstein R; Kopylov U; Dotan I; Chowers Y; Eliakim R; Ben-Horin S
    Aliment Pharmacol Ther; 2016 Jun; 43(12):1293-9. PubMed ID: 27091119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.